ZNF671 methylation test in cervical scrapings for cervical intraepithelial neoplasia grade 3 and cervical cancer detection.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37557178.
- Also identified by DOI 10.1016/j.xcrm.2023.101143 and PMC identifier 10439250.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Effective triage of high-risk human papillomavirus (hrHPV)+ women is warranted to avoid unnecessary referral and overtreatment. Molecular triage tests have recently begun to impact cervical intraepithelial neoplasia grade 3 (CIN3) or cervical cancer (CC), termed CIN3+, detection. We find that zinc finger protein 671 methylation (ZNF671<sup>m</sup>) test has superior performance for CIN3+ detection in all single molecular triage tests, including HPV16/18 genotyping, paired box gene 1 methylation (PAX1<sup>m</sup>), and ZNF671<sup>m</sup>, in the training set. Using ZNF671<sup>m</sup> test instead of Thinprep cytologic test (TCT) as a single triage strategy or as a combined triage strategy with HPV16/18 genotyping has achieved comparable sensitivity but higher specificity for CIN3+ detection among 391 hrHPV+ women in the validation set. Little attention has been paid to the women with hrHPV- status but detected CIN3+. We find that the CIN3+ risk after a negative result could be reduced further by triage using ZNF671<sup>m</sup> in hrHPV- patients.
Medical subject headings
- Uterine Cervical Neoplasms
- Uterine Cervical Dysplasia